More Americans with diabetes are now having their eyes checked for a leading cause of blindness using artificial intelligence.
LumineticsCore™ (formerly known as IDx-DR), an FDA-cleared AI system that detects diabetic retinopathy, does not require a physician to interpret the images or results. This allows patients who are at high risk for this blinding eye disease to be tested in non-eye care settings.
“In the short time we’ve been using LumineticsCore (formerly known as IDx-DR), we’ve already identified patients we believe may have the disease that has gone undetected for years,” says Dr. Madhu Mohan, an endocrinologist at Riverside Medical Associates in Riverdale, MD. “This is a truly eye-opening experience – that helped confirm my decision to adopt the system,” said Mohan.
More than 30 million Americans have diabetes, and an estimated 24,000 loose vision each year from diabetic retinopathy, a complication of diabetes. If caught in its early stages, vision loss and blindness are almost entirely preventable, yet only about half of people with diabetes get regular eye exams.
Healthcare providers who are currently testing for diabetic retinopathy may find LumineticsCore (formerly known as IDx-DR) to be a valuable tool to increase efficiency and patient throughput.